Trial purpose
Cancer treatment
Tumor type
Genitourinary
Clinical summary
Summary
This is a randomised trial with active comparator and experimental arms. Participants in the Active Comparator arm will receive the standard of care treatment of ipilimumab/nivolumab alone. Induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment. Participants in the Experimental Arm will receive the standard of care treatment if I/N plus primary disease SBRT. Induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of immunotherapy as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
Conditions
This trial is treating patients with metastatic renal cell cancer
Eligibility
Inclusion
- Biopsy proven renal cell carcinoma of any histology.
- Imaging proven metastatic disease based on CT or MRI within 10 weeks of screening.
- Intermediate/poor risk disease based on IMDC criteria (see Appendix II).
- Primary kidney lesion amenable to SBRT.
- Eligible for standard of care delivery of ipilimumab and nivolumab (I/N) according to approved product monograph.
Exclusion
- A maximum primary renal lesion size of 20 cm or greater.
- Candidate for cytoreductive nephrectomy, unless a patient has refused cytoreductive nephrectomy (in this case, a discussion of cytoreductive nephrectomy and patient refusal must be documented).
- Treatment with prior systemic therapy in the adjuvant or metastatic setting for renal cell carcinoma.
- Previous abdominal radiation precluding SBRT.
- Kanofsky Performance (KPS) score below 60 (see Appendix III).
- History of auto-immune disorder precluding treatment with ipilimumab or nivolumab.
- History of ataxia telangiectasia or other radiation sensitivity disorders.
- Chronic corticosteroid use or other chronic immune suppressive therapy. (Participants are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses of prednisone ≤ 10 mg daily are permitted).
- Use of medicinal herbal preparations (not including medical cannabis) unless prescribed by a treating physician.
- Inability to lie flat for at least 30 minutes without moving.
- Pregnant or lactating women.
- Geographic inaccessibility for follow-up.
- Inability to provide informed consent.
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- You have been diagnosed with cancer, but have not received any treatment.
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Ontario Clinical Oncolgy Group (OCOG)
Scientific Title
Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Cancer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Get support
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
More info for carers